ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jun 2024
Last Updated on 04 Jun 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Burosumab 10 mg/mL, 20 mg/mL and 30 mg/mL solution for injection for treating X-linked hypophosphataemia (XLH) in adults and children 1 year of age and older, in line with the following criteria:
    • Patient must have a documented confirmation of PHEX pathogenic variant; or
    • Patient must have a confirmed diagnosis of XLH demonstrated by the presence of all of the following:
      • a serum phosphate concentration below the age adjusted lower limit of normal;
      • current or historical (for those with growth plate fusion) radiographic X-ray evidence of rickets;
      • renal phosphate wasting demonstrated by a ratio of tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) according to age specific normal ranges using the second morning urine void and paired serum sample measuring phosphate and creatinine; and
    • Patient must be treated by, or in consultation with, a specialist physician experienced in the diagnosis and management of XLH.

Funding status

Burosumab 10 mg/mL, 20 mg/mL and 30 mg/mL solution for injection are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.


Burosumab for treating X-linked hypophosphataemia (Published 4 Jun 24) PES Burosumab for X-linked hypophosphataemia (Published 4 Jun 24)